Blood test may spot hidden cancer cells, guiding smarter treatment for esophageal cancer
NCT ID NCT07371247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test that finds tiny traces of cancer DNA (called ctDNA-MRD) can help doctors decide who needs more treatment after standard chemoradiation for advanced esophageal cancer. About 65 people with unresectable cancer will get extra immunotherapy and chemo if their blood test shows leftover cancer cells. The goal is to see if this approach is safe and helps prevent the cancer from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTDNA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can surgery for stomach or esophageal cancer cloud the mind?
- Virtual patients could revolutionize cancer drug testing
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?